trending Market Intelligence /marketintelligence/en/news-insights/trending/xa5xjknhp6bjlpjs2hl6dq2 content esgSubNav
In This List

Kitov Pharma acquires additional stake in TyrNovo

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Kitov Pharma acquires additional stake in TyrNovo

Kitov Pharma Ltd. acquired an additional 3.1% stake in its majority owned unit TyrNovo Ltd.

The Israel-based biopharmaceutical company acquired the stake from Taoz – Company for Management and Holdings of Cos. Ltd., in exchange for 0.9% of Kitov stock, comprising 2,816,900 newly issued ordinary shares or 140,845 American depositary shares.

Kitov Pharma now owns about 97.1% of TyrNovo, with the remaining 2.9% owned by TyrNovo founder and Chief Technology Officer Hadas Reuveni.